Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Abstract

Monoclonal antibody treatment has favorable outcomes with minimal adverse effects in solid organ transplant recipients with mild to moderate COVID-19. Earlier administration of monoclonal antibody therapy appears to be more efficacious.